Skip to content

Effects of long-acting alendronate on osteoporosis with impaired glucose metabolism

Effects of long-acting alendronate on osteoporosis with impaired glucose metabolism - Fushimi Bone Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000000987
Enrollment
100
Registered
2008-02-01
Start date
2007-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

None listed

Sponsors

National Hospital Organization, Kyoto Medical Center
Lead Sponsor
National Hospital Organization, Saitama Hospital Tsuji Clinic Oishi Clinic Ogawa Clinic Kitani Clinic Taniguchi Clinic Tsukuda Clinic Higashimae Clinic Furukawa Clinic Furuke Clinic Wakabayashi Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Outpatients fullfilling the following 1) or 2) and 3) criteria 1)patients in which bone mineral density or femoral neck bone determined by DXA method is less than 70% of the young adult mean (YAM) 2)patients in which bone mineral density or femoral neck bone by DXA method is between 70% and 80% (1) postmenopausal female or (2) male patients with at least one of the following risks: excess alcohol drinking (more than 2 units/day), present smoking habit, or family history of femoral neck bone fracture 3)aged between 50 years and 85 years

Exclusion criteria

Exclusion criteria: 1) patient taking bisphosphonates 2) patients contraindicated for alendronate 3) patients under treatment of glucocorticoid or with a history of treatment for 3 years or more. 4) disease states causing secondary osteoporosis: primary hyperparathyroidism, hyperthyroidism, hypogonadism, chronic rheumatic arthritis, multiple myeloma and other hematological diseases,Cushing's syndrome, immobilization, mesotholexate 5) type I diabetes mellitus, diabetes associated with other specific diseases and pregnancy 6) patients not suitable for measuring bone mineral density due to the history of supine bone fracture 7) other various conditions in which the attending doctor decide not suitable for entry.

Design outcomes

Primary

MeasureTime frame
The first outcome is the effects of long-acting alendronate on the osteoporosis and the second outcome is the comparison of the effects between the patients with and without impaired glucose metabolism

Countries

Japan

Contacts

Public ContactMitsuhide Naruse

National Hospital Organization, Kyoto Medical Center Department Endocrinology, Clinical Research Institute for Endocrine and Metabolic Diseases

mnaruse@kyotolan.hosp.go.jp075-641-9161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026